Table 1.
Patient characteristics (n = 22 assessable patients)
| Characteristics | Median (range) | |
|---|---|---|
| Age, years | 66 (34–83) | |
| n | % | |
| Menopausal status | ||
| Premenopausal | 2 | 9 |
| Postmenopausal | 20 | 91 |
| With metastatic biopsy | 17 | 77 |
| Metastatic status | ||
| Not visceral | 5 | 23 |
| Visceral | 4 | 18 |
| Both | 13 | 59 |
| Number of metastatic sites | ||
| 1 | 8 | 36 |
| 2 | 7 | 32 |
| 3 | 6 | 27 |
| 4 | 1 | 5 |
| Previous neoadjuvant therapy | ||
| None | 20 | 91 |
| CHT | 2 | 9 |
| Previous adjuvant therapy | ||
| None | 4 | 18 |
| CHT | 8 | 36 |
| HT | 1 | 5 |
| CHT and HT | 9 | 41 |
| Metastatic disease at diagnosis | ||
| No | 21 | 95 |
| Yes | 1 | 5 |
| ER status evaluated at primary tumor | ||
| Negative | 13 | 59 |
| Positive | 9 | 41 |
| TILS expression evaluated at metastatic disease | ||
| Missing | 7 | 32 |
| <10 | 7 | 32 |
| ≥10 | 8 | 36 |
CHT = Chemotherapy; ER = estrogen receptor; HT = hormonal therapy; TILS = tumor-infiltrating leukocytes.